{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:49:07Z","timestamp":1774338547096,"version":"3.50.1"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"39","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The clinical manifestation and outcomes of thrombosis with thrombocytopenia syndrome (TTS) after adenoviral COVID-19 vaccine administration are largely unknown due to the rare nature of the disease. We aimed to analyse the clinical presentation, treatment modalities, outcomes, and prognostic factors of adenoviral TTS, as well as identify predictors for mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and Results<\/jats:title>\n                  <jats:p>PubMed, Scopus, Embase, and Web of Science databases were searched and the resulting articles were reviewed. A total of 6 case series and 13 case reports (64 patients) of TTS after ChAdOx1 nCoV-19 vaccination were included. We performed a pooled analysis and developed a novel scoring system to predict mortality. The overall mortality of TTS after ChAdOx1 nCoV-19 vaccination was 35.9% (23\/64). In our analysis, age \u226460\u2009years, platelet count &amp;lt;25\u2009\u00d7\u2009103\/\u00b5L, fibrinogen &amp;lt;150\u2009mg\/dL, the presence of intracerebral haemorrhage (ICH), and the presence of cerebral venous thrombosis (CVT) were significantly associated with death and were selected as predictors for mortality (1 point each). We named this novel scoring system FAPIC (fibrinogen, age, platelet count, ICH, and CVT), and the C-statistic for the FAPIC score was 0.837 (95% CI 0.732\u20130.942). Expected mortality increased with each point increase in the FAPIC score, at 2.08, 6.66, 19.31, 44.54, 72.94, and 90.05% with FAPIC scores 0, 1, 2, 3, 4, and 5, respectively. The FAPIC scoring model was internally validated through cross-validation and bootstrapping, then externally validated on a panel of TTS patients after Ad26.COV2.S administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Fibrinogen levels, age, platelet count, and the presence of ICH and CVT were significantly associated with mortality in patients with TTS, and the FAPIC score comprising these risk factors could predict mortality. The FAPIC score could be used in the clinical setting to recognize TTS patients at high risk of adverse outcomes and provide early intensive interventions including intravenous immunoglobulins and non-heparin anticoagulants.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehab592","type":"journal-article","created":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T19:09:44Z","timestamp":1631387384000},"page":"4053-4063","source":"Crossref","is-referenced-by-count":67,"title":["Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0253-0676","authenticated-orcid":false,"given":"Jimin","family":"Hwang","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Hyun","family":"Park","sequence":"additional","affiliation":[{"name":"Yonsei University College of Medicine , Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5632-5208","authenticated-orcid":false,"given":"Seung Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Data Science, Sejong University College of Software Convergence , Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Bee","family":"Lee","sequence":"additional","affiliation":[{"name":"Ulsan University College of Medicine , Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8193-0220","authenticated-orcid":false,"given":"Min Ho","family":"Lee","sequence":"additional","affiliation":[{"name":"Yonsei University College of Medicine , Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwang Hun","family":"Jeong","sequence":"additional","affiliation":[{"name":"College of Medicine, Gyeongsang National University , Jinju, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1337-563X","authenticated-orcid":false,"given":"Min Seo","family":"Kim","sequence":"additional","affiliation":[{"name":"Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University , Samsung Medical Center, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Yeob","family":"Kim","sequence":"additional","affiliation":[{"name":"Yonsei University College of Medicine , Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9565-5004","authenticated-orcid":false,"given":"Ai","family":"Koyanagi","sequence":"additional","affiliation":[{"name":"Parc Sanitari Sant Joan de Deu\/CIBERSAM, Universitat de Barcelona, Fundacio Sant Joan de Deu, Sant Boi de Llobregat , Barcelona, Spain"},{"name":"ICREA, Pg. Lluis Companys 23 , Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2326-1820","authenticated-orcid":false,"given":"Louis","family":"Jacob","sequence":"additional","affiliation":[{"name":"Parc Sanitari Sant Joan de Deu\/CIBERSAM, Universitat de Barcelona, Fundacio Sant Joan de Deu, Sant Boi de Llobregat , Barcelona, Spain"},{"name":"Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines , Montigny-le-Bretonneux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Yong","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yonsei University College of Medicine , Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaewoo","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Yonsei University College of Medicine , Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Keon","family":"Yon","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seoul National University Hospital, Seoul National University College of Medicine , Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Il","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yonsei University College of Medicine , Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5340-9833","authenticated-orcid":false,"given":"Lee","family":"Smith","sequence":"additional","affiliation":[{"name":"The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University , Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"2022102514552991700_ehab592-B1","article-title":"Coronavirus Resource Center","author":"Johns","year":"2021","journal-title":"COVID-19 Map [Internet]"},{"key":"2022102514552991700_ehab592-B2","author":"Gavi","year":"2021"},{"key":"2022102514552991700_ehab592-B3","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/S1473-3099(20)30773-8","article-title":"What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2","volume":"21","author":"Hodgson","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022102514552991700_ehab592-B4","year":"2021"},{"key":"2022102514552991700_ehab592-B5","year":"2021"},{"key":"2022102514552991700_ehab592-B6","year":"2021"},{"key":"2022102514552991700_ehab592-B7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"2022102514552991700_ehab592-B8","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102514552991700_ehab592-B9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102514552991700_ehab592-B10","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102514552991700_ehab592-B11","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102514552991700_ehab592-B12","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102514552991700_ehab592-B13","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.thromres.2021.04.001","article-title":"Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination","volume":"202","author":"Franchini","year":"2021","journal-title":"Thromb Res"},{"key":"2022102514552991700_ehab592-B14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbi.2021.04.006","article-title":"Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination\u2014a report of two UK cases","volume":"95","author":"Mehta","year":"2021","journal-title":"Brain Behav Immun"},{"key":"2022102514552991700_ehab592-B15","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1111\/jth.15346","article-title":"Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)","volume":"19","author":"Thaler","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2022102514552991700_ehab592-B16","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1182\/blood.2021011958","article-title":"Prothrombotic immune thrombocytopenia after COVID-19 vaccine","volume":"138","author":"Tiede","year":"2021","journal-title":"Blood"},{"key":"2022102514552991700_ehab592-B17","year":"2021"},{"key":"2022102514552991700_ehab592-B18","year":"2021"},{"key":"2022102514552991700_ehab592-B19","doi-asserted-by":"crossref","first-page":"n931","DOI":"10.1136\/bmj.n931","article-title":"AstraZeneca vaccine: blood clots are \u2018extremely rare\u2019 and benefits outweigh risks, regulators conclude","volume":"373","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"2022102514552991700_ehab592-B20","doi-asserted-by":"crossref","first-page":"n958","DOI":"10.1136\/bmj.n958","article-title":"Thrombosis after covid-19 vaccination","volume":"373","author":"Hunter","year":"2021","journal-title":"BMJ"},{"key":"2022102514552991700_ehab592-B21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMcp1411910","article-title":"Clinical practice. Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N Engl J Med"},{"key":"2022102514552991700_ehab592-B22","doi-asserted-by":"crossref","first-page":"n883","DOI":"10.1136\/bmj.n883","article-title":"Covid-19: EMA defends AstraZeneca vaccine as Germany and Canada halt rollouts [Internet]","volume":"373","author":"Dyer","year":"2021","journal-title":"BMJ"},{"key":"2022102514552991700_ehab592-B23","year":"2021"},{"key":"2022102514552991700_ehab592-B24","year":"2021"},{"key":"2022102514552991700_ehab592-B25","doi-asserted-by":"crossref","first-page":"n196","DOI":"10.1136\/bmj.n196","article-title":"Covid-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust","volume":"372","author":"Thiagarajan","year":"2021","journal-title":"BMJ"},{"key":"2022102514552991700_ehab592-B26","doi-asserted-by":"crossref","first-page":"n631","DOI":"10.1136\/bmj.n631","article-title":"Covid-19: 237m vaccine doses to be distributed worldwide over next three months","volume":"372","author":"Rimmer","year":"2021","journal-title":"BMJ"},{"key":"2022102514552991700_ehab592-B27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2022102514552991700_ehab592-B28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5694\/mja2.51135","article-title":"The first known case of vaccine-induced thrombotic thrombocytopenia in Australia","volume":"215","author":"Hocking","year":"2021","journal-title":"Med J Aust"},{"key":"2022102514552991700_ehab592-B29","first-page":"343","article-title":"A case of vaccine-induced immune thrombotic thrombocytopenia with massive artero-venous thrombosis","volume":"19","author":"Turi","year":"2021","journal-title":"Blood Transfus"},{"key":"2022102514552991700_ehab592-B30","doi-asserted-by":"crossref","DOI":"10.1097\/CCM.0000000000005105","article-title":"using nonheparin anticoagulant to treat a near-fatal case with multiple venous thrombotic lesions during ChAdOx1 nCoV-19 vaccination-related vaccine-induced immune thrombotic thrombocytopenia","author":"Bersinger","year":"2021","journal-title":"Crit Care Med"},{"key":"2022102514552991700_ehab592-B31","doi-asserted-by":"crossref","first-page":"E906","DOI":"10.1503\/cmaj.210795","article-title":"Limb ischemia and pulmonary artery thrombosis afer the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine: a case of vaccine-induced immune thrombotic thrombocytopenia","volume":"193","author":"Jones","year":"2021","journal-title":"CMAJ"},{"key":"2022102514552991700_ehab592-B32","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2021-326984","article-title":"Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","author":"Al-Mayhani","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2022102514552991700_ehab592-B33","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3390\/jcm10081599","article-title":"Thrombocytopenia and intracranial venous sinus thrombosis after \u2018COVID-19 Vaccine AstraZeneca\u2019 exposure","volume":"10","author":"Wolf","year":"2021","journal-title":"J Clin Med"},{"key":"2022102514552991700_ehab592-B34","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105938","article-title":"Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular coagulation and death following the ChAdOx1 nCoV-19 vaccine","volume":"30","author":"Aladdin","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2022102514552991700_ehab592-B35","doi-asserted-by":"crossref","first-page":"e243931","DOI":"10.1136\/bcr-2021-243931","article-title":"ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST)","volume":"14","author":"Suresh","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2022102514552991700_ehab592-B36","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S0140-6736(21)01238-1","article-title":"SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban","volume":"397","author":"Guetl","year":"2021","journal-title":"Lancet"},{"key":"2022102514552991700_ehab592-B37","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(21)00871-0","article-title":"Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination","volume":"397","author":"Muster","year":"2021","journal-title":"Lancet"},{"key":"2022102514552991700_ehab592-B38","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab237","article-title":"COVID-19 vaccine induced prothrombotic immune thrombocytopenia","author":"Xie","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102514552991700_ehab592-B39","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/jth.15347","article-title":"Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine","volume":"19","author":"Blauenfeldt","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2022102514552991700_ehab592-B40","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2021.7517","article-title":"US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S Vaccination, March 2 to April 21, 2021","volume":"325","author":"See","year":"2021","journal-title":"JAMA"},{"key":"2022102514552991700_ehab592-B41","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMc2105869","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S vaccination","volume":"384","author":"Muir","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102514552991700_ehab592-B42","doi-asserted-by":"crossref","first-page":"E346","DOI":"10.1002\/ajh.26265","article-title":"Vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism","volume":"96","author":"Abou-Ismail","year":"2021","journal-title":"Am J Hematol"},{"key":"2022102514552991700_ehab592-B43","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/ajh.26258","article-title":"Thrombocytopenia and splanchnic thrombosis after Ad26.COV2.S vaccination successfully treated with transjugular intrahepatic portosystemic shunting and thrombectomy","volume":"96","author":"Dhoot","year":"2021","journal-title":"Am J Hematol"},{"key":"2022102514552991700_ehab592-B44","doi-asserted-by":"crossref","first-page":"E301","DOI":"10.1002\/ajh.26237","article-title":"Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination","volume":"96","author":"George","year":"2021","journal-title":"Am J Hematol"},{"key":"2022102514552991700_ehab592-B45","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1093\/ehjcvp\/pvab036","article-title":"Incidence of cerebral venous thrombosis and COVID-19 vaccination: possible causale effect or just chance?","volume":"7","author":"de Simone","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2022102514552991700_ehab592-B46","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1161\/STR.0b013e31820a8364","article-title":"Diagnosis and management of cerebral venous thrombosis","volume":"42","author":"Saposnik","year":"2011","journal-title":"Stroke"},{"key":"2022102514552991700_ehab592-B47","year":"2021"},{"key":"2022102514552991700_ehab592-B48","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1182\/blood-2014-01-549741","article-title":"Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder","volume":"123","author":"Warkentin","year":"2014","journal-title":"Blood"},{"key":"2022102514552991700_ehab592-B49","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/blood-2010-06-289835","article-title":"Improving specificity in HIT testing","volume":"116","author":"Aster","year":"2010","journal-title":"Blood"},{"key":"2022102514552991700_ehab592-B50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.tmrv.2006.05.001","article-title":"Testing for heparin-induced thrombocytopenia antibodies","volume":"20","author":"Warkentin","year":"2006","journal-title":"Transfus Med Rev"},{"key":"2022102514552991700_ehab592-B51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/ijlh.12993","article-title":"Laboratory diagnosis of heparin-induced thrombocytopenia","volume":"41","author":"Warkentin","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"2022102514552991700_ehab592-B52","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1182\/blood-2019-125293","article-title":"Comparison of two different ELISA methods for heparin-induced thrombocytopenia (HIT) screening on an automated ELISA platform","volume":"134","author":"Mardovina","year":"2019","journal-title":"Blood"},{"key":"2022102514552991700_ehab592-B53","doi-asserted-by":"crossref","DOI":"10.1111\/jth.15423","article-title":"Anti-PF4 testing for vaccine-induced immune thrombocytopenia and thrombosis and heparin induced thrombocytopenia: results from a UK National External Quality Assessment Scheme exercise April 2021","author":"Reilly-Stitt","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2022102514552991700_ehab592-B54","first-page":"2598; author reply 2598","article-title":"Heparin-induced thrombocytopenia","volume":"355","author":"Saad","year":"2006","journal-title":"N Engl J Med"},{"key":"2022102514552991700_ehab592-B55","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3390\/jcm9041226","article-title":"Detection of platelet-activating antibodies associated with heparin-induced thrombocytopenia","volume":"9","author":"Tardy","year":"2020","journal-title":"J Clin Med"},{"key":"2022102514552991700_ehab592-B56","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/MBC.0b013e3282a167cc","article-title":"Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition","volume":"19","author":"Kelton","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2022102514552991700_ehab592-B57","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/01.CCM.0000119426.34340.E2","article-title":"Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy","volume":"32","author":"LaMonte","year":"2004","journal-title":"Crit Care Med"},{"key":"2022102514552991700_ehab592-B58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/jnnp.70.1.105","article-title":"Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patients. For The Cerebral Venous Sinus Thrombosis Study Group","volume":"70","author":"de Bruijn","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2022102514552991700_ehab592-B59","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.4161\/hv.24696","article-title":"The effect of aging of the immune system on vaccination responses","volume":"9","author":"Lord","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"2022102514552991700_ehab592-B60","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2020.03.017","article-title":"Influence of immune aging on vaccine responses","volume":"145","author":"Gustafson","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2022102514552991700_ehab592-B61","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv"},{"key":"2022102514552991700_ehab592-B62","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/pgmj.2007.059188","article-title":"Heparin induced thrombocytopenia: diagnosis and management update","volume":"83","author":"Ahmed","year":"2007","journal-title":"Postgrad Med J"},{"key":"2022102514552991700_ehab592-B63","author":"Pavord","year":"2021"},{"key":"2022102514552991700_ehab592-B64","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMe2106315","article-title":"SARS-CoV-2 Vaccine-induced immune thrombotic thrombocytopenia","volume":"384","author":"Cines","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102514552991700_ehab592-B65","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.chest.2017.03.050","article-title":"IVIg for treatment of severe refractory heparin-induced thrombocytopenia","volume":"152","author":"Padmanabhan","year":"2017","journal-title":"Chest"},{"key":"2022102514552991700_ehab592-B66","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17474086.2019.1636645","article-title":"High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review","volume":"12","author":"Warkentin","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"2022102514552991700_ehab592-B67","year":"2021"},{"key":"2022102514552991700_ehab592-B68","doi-asserted-by":"crossref","first-page":"102681","DOI":"10.1016\/j.jaut.2021.102681","article-title":"Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines","volume":"122","author":"Hwang","year":"2021","journal-title":"J Autoimmun"},{"key":"2022102514552991700_ehab592-B69","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1055\/a-1499-0119","article-title":"SARS-CoV-2 vaccine and thrombosis: an expert consensus on vaccine-induced immune thrombotic thrombocytopenia","volume":"121","author":"Elalamy","year":"2021","journal-title":"Thromb Haemost"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/39\/4053\/46626863\/ehab592.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/39\/4053\/46626863\/ehab592.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T17:46:17Z","timestamp":1666719977000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/39\/4053\/6372957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":69,"journal-issue":{"issue":"39","published-online":{"date-parts":[[2021,9,21]]},"published-print":{"date-parts":[[2021,10,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab592","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,14]]},"published":{"date-parts":[[2021,9,21]]}}}